Abstracts tagged "anti-TNF therapy"

Abstract Number: 626 • 2016 ACR/ARHP Annual Meeting
Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients
Branca Souza¹, Juliana Valim², Fernanda Chaer³, Fernanda Guimarães⁴ and Verônica Lima⁵, ¹Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ²Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, ³Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil
Background/Purpose: Evaluate the reason of exchange of biologic therapy in patients with rheumatoid arthritis and describe the frequency of remission or low activity, according to…
Abstract Number: 1721 • 2016 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis Evolution during 5 Years of Anti-Tnfalpha Treatment in Psoriatic Arthritis Patients: Preliminary Data
Augusta Ortolan¹, Giovanni Boschetti², Mariagrazia Lorenzin¹, Giulia Cherobin³, Leonardo Punzi³, Massimo Puato² and Roberta Ramonda³, ¹Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy, ²Clinica Medica III, Department of Medicine DIMED, University of Padova, Padova, Italy, ³Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
Background/Purpose: Psoriatic Arthritis (PsA) is associated with increased morbility and mortality and an accelerated atherosclerosis. Influence of anti-TNFalpha treatment (a widely used therapy in PsA)…
Abstract Number: 2652 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis and Excess Mortality Associated with Treatments: a Systematic Review and Meta-Analysis
Manon Redondin¹, B Combe², Cécile Gaujoux-Viala³, Jacques Morel⁴ and Cédric Lukas⁵, ¹CHU Lapeyronie, University of Montpellier, France, ²Immuno-Rhumatologie, CHU Lapeyronie, University of Montpellier, France, ³CHU Nîmes, University of Montpellier, France, ⁴Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ⁵Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France
Background/Purpose: Patients with rheumatoid arthritis (RA) have a lower life expectancy than general population. The impact of RA treatments on global mortality is not…
Abstract Number: 252 • 2016 ACR/ARHP Annual Meeting
Cytokine Profiles of Korean Patients with Adult Onset Still’s Disease Treated with Biologic Agents
Seung Taek Song¹, SuMan Kang², Sung Won Lee³, Seoung Wan Nam², Hyukhee Kwon² and Dae-Hyun Yoo⁴, ¹Division of Rheumatology, Department of Internal Medicine, Cheongju St. Mary's Hospital, Cheongju, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, ³Department of Rheumatology, Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Several studies have reported that pro-inflammatory cytokines including interleukin (IL)-1, IL-6,…
Abstract Number: 637 • 2016 ACR/ARHP Annual Meeting
Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs
Natalie Boytsov¹, George W. Reed², Leslie R Harrold^2,3, Xiang Zhang¹, Carol L Gaich¹, Cynthia J Larmore¹, Ying Shan², S Rebello⁴ and Andre B. Araujo¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Corrona, LLC, Southborough, MA, ³UMass Medical School, Worcester, MA, ⁴Epidemiology, Corrona, Southborough, MA
Background/Purpose: The purpose of this study was to describe biologic initiation patterns over a 1-year follow-up period in rheumatoid arthritis (RA) patients with moderate…
Abstract Number: 1736 • 2016 ACR/ARHP Annual Meeting
Efficacy of TNF Inhibitors in Axial Spondyloarthritis According to the Presence of Objective Signs of Inflammation: A Multicentric Retrospective Study
Celine Vidal¹, Cédric Lukas², Bernard Combe³, Francis Berenbaum⁴, Christian Jorgensen⁵, Jeremie Sellam⁶ and Jacques Morel⁷, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ³Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁴Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ⁵Inserm u844, Unite ImmunoRhumatologie Therapeutique, Montpellier, France, ⁶Rheumatology, Saint-Antoine Hospital, Paris, France, ⁷Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France
Background/Purpose: TNF inhibitors (TNFi) are effective treatment in radiographic and non-radiographic axial spondyloarthritis (r-axSpA and nr-axSpA). Nr-axSpA have lower response rate in case of absence…
Abstract Number: 2718 • 2016 ACR/ARHP Annual Meeting
Plasma Levels of the M2 Macrophage Markers, CD163 and CD206, Changes Reversely and Soluble CD163 Is Associated with Disease Activity in Spondyloarthritis
Line Dam Heftdal^1,2, René Østgård^3,4, Malene Hvid^3,5, Bent Deleuran^2,3,5, Holger Jon Møller⁵ and Stinne Greisen^2,3, ¹Department of Biomedicine, Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Biomedicine, Aarhus University, Aarhus, Denmark, ⁴Department of Rheumatology, Regional Hospital Silkeborg, Silkeborg, Denmark, ⁵Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: Spondyloarthritis (SpA) covers a group of interrelated auto-inflammatory disorders where TNFa is a central mediator of disease. T cells and macrophages are abundant in…
Abstract Number: 433 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Latent Tuberculosis and Hepatitis B Found after Systematic Screening of Patients Starting with Biological Therapy in a Low-Endemic Area
Marin de Jong^1,2, Danielle Roosen¹, Andy Peters¹, Valerie Verstraeten³, Marieke Pierik¹ and A. van Tubergen⁴, ¹Department of Internal Medicine, division of Gastroenterology, Maastricht University Medical Centre, Maastricht, Netherlands, ²NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, Netherlands, ³Department of Dermatology, Maastricht University Medical Centre, Maastricht, Netherlands, ⁴Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Biologicals are a powerful treatment option for moderate to severe immune-mediated inflammatory diseases (IMID). Since biologicals modulate the immune system, the risk for reactivation…
Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting
Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Theodora Bejan-Angoulvant¹, David Ternant², Fadela Daoued³, Frédéric Medina³, Louis Bernard⁴, Saloua Mammou³, Gilles Paintaud² and Denis Mulleman⁵, ¹Service de Pharmacologie Clinique, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ²Laboratoire de Pharmacologie-Toxicologie, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ³Service de Rhumatologie, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁴Service des Maladies Infectieuses, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁵Service de Rhumatologie, Rheumatology department, François-Rabelais University, CNRS 7292, CHRU de Tours, Tours, France
Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…
Abstract Number: 2005 • 2016 ACR/ARHP Annual Meeting
Exploring the Window of Opportunity for Drug-Free Clinical Remission in Patients with Active, Very Early Peripheral Spondyloarthritis
Philippe Carron¹, Gaëlle Varkas², Heleen Cypers², Liesbet Van Praet¹, Dirk Elewaut² and Filip van Den Bosch¹, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium
Background/Purpose: To evaluate drug-free sustained clinical remission and clinical relapse after induction therapy with golimumab in patients with active peripheral Spondyloarthritis (pSpA) in a very…
Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting
The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients
Mark Berman¹, Daphna Paran¹, Yonatan Wolman¹ and Ori Elkayam², ¹Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…
Abstract Number: 604 • 2015 ACR/ARHP Annual Meeting
Calprotectin and TNF Antagonist Serum Trough Levels Identify Active Ultrasound Synovitis in Rheumatoid Arhritis and Psoriatic Arthritis Patients in Remission or Low Disease Activity
Jose Inciarte-Mundo¹, Julio Ramírez¹, Virginia Ruiz-Esquide¹, M. Victoria Hernández¹, Oscar Camacho¹, Sonia Cabrera-Villalba¹, Andrea Cuervo¹, Mariona Pascal², Jordi Yagüe², Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ²Immunology Department, Hospital Clinic i Provincial, Barcelona, Spain
Background/Purpose: An accurate assessment of disease activity is needed in Rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients in remission or low disease activity for…
Abstract Number: 1331 • 2015 ACR/ARHP Annual Meeting
Change in MRI in Patients with Spondyloarthritis Treated with Anti-TNF Agents : Systematic Review of the Literature
Gisèle KHOURY¹, BG Combe² and Cédric Lukas³, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²Lapeyronie, Montpellier, France, ³Hopital Lapeyronie, Montpellier, France
Background/Purpose: The follow-up of axial spondyloarthritis (SpA) remains difficult in clinical practice, mainly based on patient-reported outcomes, whereas objective parameters in disease monitoring are often…
Abstract Number: 2140 • 2015 ACR/ARHP Annual Meeting
Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Meghna Jani¹, William G Dixon², Lianne Kearsley-Fleet³, Ian N. Bruce^4,5, Hector Chinoy^6,7, Anne Barton^6,8, Mark Lunt⁹, Kath Watson³, Deborah P.M. Symmons¹, Kimme L. Hyrich³ and on behalf of the BSRBR-RA, ¹Centre for Musculoskeletal Research, University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁵Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁶Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁸NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁹Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom
Background/Purpose: The association between TNF inhibitors (TNFis) and vasculitis-like events, possibly secondary to induction of autoantibodies, has been well reported. However, the incidence, drug-specific differences…
Abstract Number: 2867 • 2015 ACR/ARHP Annual Meeting
Impact of Timely Versus Delayed Use of Anti-Tumor Necrosis Factor (TNF) Biologics in the Treatment of Psoriatic Arthritis: Results from a Modeling Study
Vibeke Strand¹, M. Elaine Husni², Zheng-Yi Zhou³, James Signorovitch³, Jenny Griffith⁴, Yichen Zhong³ and Arijit Ganguli⁴, ¹Stanford University, Palo Alto, CA, ²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ³Analysis Group, Inc., Boston, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Progression of psoriatic arthritis (PsA) can lead to irreversible joint damage and functional impairment. TNF inhibitors (TNFi’s) have been shown to improve signs and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].